The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 36, No. 2, pp. 225-230. DOI 10.1345/aph.1A152
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frackiewicz, E.
Right arrow Articles by Cutler, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frackiewicz, E.
Right arrow Articles by Cutler, N.

Research Articles

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa

EJ Frackiewicz, SS Jhee, TM Shiovitz, J Webster, C Topham, RC Dockens, D Whigan, DE Salazar, and NR Cutler

OBJECTIVE: To investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the dopamine transporter antagonist brasofensine (BMS-204756) in patients with Parkinson's disease receiving levodopa/carbidopa treatment. METHODS: A 4-period crossover study was performed in 8 men (mean age 66 y) with moderate Parkinson's disease (Hoehn-Yahr stage II-IV). A dose escalation study was used in which each patient was given a single oral dose of brasofensine 0.5, 1, 2, or 4 mg, which was coadministered with the patient's usual dose of levodopa/carbidopa. RESULTS: The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases. Exposure to brasofensine (based on AUC0-infinity) increased at a rate greater than proportional to dose. Based on the motor performance subscale of the Unified Parkinson's Disease Rating Scale, no change in patient disability was observed at any dose level. CONCLUSIONS: Brasofensine was safe and well tolerated in the patient cohort studied at daily doses of up to 4 mg. Adverse events were generally mild in intensity, and included headache, insomnia, phlebitis, dizziness, ecchymosis, and vomiting.


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Zhu, D. B. Whigan, S. Y. Chang, and R. C. Dockens
Disposition and Metabolism of [14C]Brasofensine in Rats, Monkeys, and Humans
Drug Metab. Dispos., January 1, 2008; 36(1): 24 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. G. Nutt, J. H. Carter, and N. E. Carlson
Effects of Methylphenidate on Response to Oral Levodopa: A Double-blind Clinical Trial
Arch Neurol, March 1, 2007; 64(3): 319 - 323.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. K. Madras, M. A. Fahey, M. Goulet, Z. Lin, J. Bendor, C. Goodrich, P. C. Meltzer, D. R. Elmaleh, E. Livni, A. A. Bonab, et al.
Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 570 - 585.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.